

Freedom of Information Request

Ref: 25-688

21 August 2025

By Email

Dear Sir/Madam

Thank you for your request for information under the Freedom of Information Act 2000. The Trust's response is as follows:

- We can confirm that we do hold the information you are requesting

I would be grateful if you could provide information regarding your hospitals clinical practice on the timing of methotrexate (MTX) level monitoring in patients receiving high-dose methotrexate (HDMTX) therapy. Specifically, I am seeking the following:

Adult Patients

1. For adult patients with acute lymphoblastic leukaemia (ALL) receiving HDMTX, at what time point does your centre take the first MTX level?

This will be as per protocol that is being followed. For example, the patients under the ALLTogether protocol, the time the first methotrexate plasma concentration is determined by the trial protocol as below.

The expected methotrexate plasma concentrations are given in the following table.

Time from start of methotrexate	Serum creatinine measurement	Methotrexate-level measurement	Methotrexate-plasma concentration expected	Folinic acid dose
24 hours	Yes	Yes	<150µmol/L	
36 hours	(yes)*	(yes)*	<3µmol/L	
42 hours	Yes	Yes	≤1µmol/L	15mg/m ² intravenous
48 hours	Yes	Yes	≤0.4µmol/L	15mg/m ² intravenous
54 hours		(yes)*		15mg/m ² intravenous

2. For adult patients with osteosarcoma receiving HDMTX, at what time point does your centre take the first MTX level?

24 hours after the start of the methotrexate infusion.

3. For adult patients with non-Hodgkin's lymphoma receiving HDMTX, at what time point does your centre take the first MTX level?

48 hours after the start of the methotrexate infusion.

Paediatric Patients

1. For paediatric patients with acute lymphoblastic leukaemia (ALL) receiving HDMTX, at what time point does your centre take the first MTX level?

24 hours after start of infusion

2. For paediatric patients with osteosarcoma receiving HDMTX, at what time point does your centre take the first MTX level?

24 hours after start of infusion

3. For paediatric patients with non-Hodgkin's lymphoma receiving HDMTX, at what time point does your centre take the first MTX level?

48 hours after start of infusion.

This concludes our response. We trust that you find this helpful, but please do not hesitate to contact us directly if we can be of any further assistance.

If, after that, you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to:

Data Protection Officer
University Hospitals Bristol and Weston NHS Foundation Trust
Trust Headquarters
Marlborough Street
Bristol
BS1 3NU

Please remember to quote the reference number above in any future communications.

If you are not content with the outcome of the internal review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF

Publication

Please note that this letter and the information included/attached will be published on our website as part of the Trust's Freedom of Information Publication Log. This is because

information disclosed in accordance with the Freedom of Information Act is disclosed to the public, not just to the individual making the request. We will remove any personal information (such as your name, email and so on) from any information we make public to protect your personal information.

To view the Freedom of Information Act in full please click [here](#).

Yours sincerely

Freedom of Information Team
University Hospitals Bristol and Weston NHS Foundation Trust